Sema4 Signal WES/WTS
Sema4 Signal PanCancer

Whole exome and transcriptome sequencing solutions for solid tumor and hematological cancers

We are excited to announce the upcoming launch of **Sema4 Signal WES/WTS (~20,000 genes)** and **Sema4 Signal PanCancer (>2,000 cancer-related genes)**, two comprehensive testing solutions designed for all solid tumor and hematological malignancies. These advanced offerings integrate whole exome sequencing (WES), whole transcriptome sequencing (WTS), and tumor-normal matched analysis to deliver insights across both somatic and germline* mutations to help providers:

- Determine diagnoses and prognoses for solid tumor or hematological cancers
- Identify and use available targeted therapies
- Make decisions regarding suitability of current clinical trials
- Learn about certain hereditary contributions to various cancer types*
- Gain insight regarding secondary findings per ACMG guidelines** (with consent)

Powerful insights to help personalize cancer treatment

Our tumor-normal matched DNA analysis and RNA-seq (tumor only) analysis cover these alterations and features based on 250x tumor coverage and 100x normal coverage across all genes, and 100M RNA reads:

- Single nucleotide variants (SNVs)
- Insertion/Deletions (INDELs)
- Copy number variants (CNVs)
- Fusions
- Certain splice variants
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Arm- and chromosome-level aneuploidies

Samples accepted:

FFPE Fresh frozen Bone marrow Blood Saliva Buccal swab

* Please note that while some inherited genetic changes may be detected, these tests do not replace comprehensive germline testing. If an inherited condition is suspected in the patient or their family member(s), a different test with the purpose of examining germline genetic changes based on family and/or personal history may be appropriate.

**ACMG Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing (ACMG SF v2.0). PMID: 27854360

Delivering differentiated patient care insights

Sema4 Signal WES/WTS and Sema4 Signal PanCancer will be delivered as end-to-end solutions through our Sema4 Provider Portal, where providers can order testing, track samples, and review results, including a dashboard view of detected variants.

Results are returned in a comprehensive, easy-to-interpret report that includes patient-specific, up-to-date information on clinical significance of detected alterations, targeted therapies, clinical trials, and diagnostic and prognostic insights. Sema4 offers genetic counseling for all pathogenic and likely pathogenic germline findings that are reported.

Providers will also have access to innovative Patient Journey and Cohort Builder tools* built on our Centrellis™ health intelligence platform. These proprietary tools provide an interactive timeline visualization of the patient's health journey and enable comparison to relevant patient cohorts to inform data-driven decisions about patient care and support clinical trial planning and recruitment.

Sema4 Signal WES/WTS and Sema4 Signal PanCancer end-to-end precision oncology solutions



Data-driven precision oncology solutions

Sema4 is a patient-centered health intelligence company at the vanguard of transformative healthcare. We are founded on the belief that the best way to optimize wellness is to understand individuals holistically as complex networks of molecular and clinical information. By applying AI-based algorithms to these networks, we derive the powerful insights that drive Sema4 Signal, our family of personalized oncology care solutions.

→ To learn more about our oncology solutions and services, please visit **sema4.com**, call **833-486-6260**, or email **ClientServicesOncology@sema4.com**

* Currently available for research purposes only.

sema4.com © 2019 Sema4. All rights reserved. LLP0353E0919

sema4